Hypophosphatemic Rickets in Norway

Hyperphosphatemia Clinical Trial

Official title:

Hypophosphatemic Rickets in Norway

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01057186
• Other study ID #: 21922
• Status: Active, not recruiting
• Phase: N/A
• First received: January 26, 2010
• Last updated: August 30, 2016
• Start date: December 2009

Study information

• Verified date: August 2016
• Source: Haukeland University Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Norway: Norwegian Social Science Data ServicesNorway:National Committee for Medical and Health Research Ethics
• Study type: Observational

Clinical Trial Summary

The purpose of the study is to do a follow-up survey of all individuals with hereditary hypophosphatemia in Norway, focusing on manifestations in childhood and adolescence. The investigators also want to study phenotype-genotype associations, and look for new genes, in all forms of hereditary hypo and hyperphosphatemia.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 80
• Est. primary completion date: December 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• All patients in the Norwegian population with hereditary hypophosphatemia, with or without rickets

• Patients in the Norwegian population with hereditary hyperphosphatemia

Exclusion Criteria:

Study Design

Observational Model: Cohort

Related Conditions & MeSH terms

• Familial Hypophosphatemic Rickets
• Hyperphosphatemia
• Hypophosphatemia
• Hypophosphatemia, Familial
• Rickets

Intervention

Dietary Supplement:
• Alfacalcidol; phosphate.
Individual dosage form and dosage depending on phenotype and underlying cause.

Drug:
• Sevelamer
Pills. Individual dosage depending on clinical symptoms/phenotype.

Locations

Country	Name	City	State
Norway	Haukeland University Hospital, Childrens departement	Bergen

Sponsors (1)

Lead Sponsor	Collaborator
Haukeland University Hospital

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Growth	Change i height z-score from time of diagnosis to last registered consultation.	Up to 18 years	No